Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

about

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

Item

http://www.wikidata.org/entity/Q55401717

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@en

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@nl

type

Item

label

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@en

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@nl

prefLabel

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@en

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@nl

P1476

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

@en

P2093

Fei Yu

http://www.w3.org/2001/XMLSchema#string

Jing Ke

http://www.w3.org/2001/XMLSchema#string

Jingjing Zhang

http://www.w3.org/2001/XMLSchema#string

Junling Liu

http://www.w3.org/2001/XMLSchema#string

Qing Tian

http://www.w3.org/2001/XMLSchema#string

Ran Lu

http://www.w3.org/2001/XMLSchema#string

Rui Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action

Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells

Hyperglycemia, tumorigenesis, and chronic inflammation.

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Incretin-mimetic therapies and pancreatic disease: a review of observational data.

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

P304

e0198938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0198938

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tianpei Hong

Jin Yang

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29897998

http://www.w3.org/2001/XMLSchema#string

P921

metformin

P932

5999272

http://www.w3.org/2001/XMLSchema#string